Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (Nasdaq: PACB) designs, develops, and manufactures sequencing systems and related products based on its Single-Molecule Real-Time technology and HiFi long-read sequencing. Its instruments, consumables, reagents, software, and sequencing services support analysis of genomes,… From the company’s description.
Over the twelve months to Sep 30, 2026, Pacific Biosciences of California, Inc. reported revenue of $161.39M, up 4.4% from a year earlier, and a net loss of $131.23M. Its operating margin was −81.3%, and operations used $136.95M in cash. In fiscal 2025, it reported revenue of $160.00M, up 3.9% from fiscal 2024, and a net loss of $546.38M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pacific Biosciences of California, Inc. does
In the company’s own words
Pacific Biosciences of California, Inc. (Nasdaq: PACB) designs, develops, and manufactures sequencing systems and related products based on its Single-Molecule Real-Time technology and HiFi long-read sequencing. Its instruments, consumables, reagents, software, and sequencing services support analysis of genomes, transcriptomes, and epigenomes, including applications in human genomics, oncology, infectious disease, and plant and animal sciences. Customers include academic and government research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural businesses. Its instrument portfolio includes the Revio, Vega, and Sequel systems; other offerings include SMRT Cells, Kinnex RNA kits, and PureTarget targeted-sequencing panels and kits. The company completed a sale of certain short-read sequencing technology assets in January 2026. As of December 31, 2025, it had 485 full-time employees. Its website is www.pacb.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- MENLO PARK, CA
- Fiscal year end
- December
- CIK
- 1299130
- SIC
- 3826
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pacific Biosciences of California, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pacific Biosciences of California, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pacific Biosciences of California, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pacific Biosciences of California, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pacific Biosciences of California, Inc.'s last four quarterly filings that the numbers alone won't show?”